Article

Ars Technica on 2019-10-23 12:30

Alzheimer’s drug that failed early tests now dubbed effective, heads to FDA

An analysis in March suggested that testing the drug was futile.

Michel Vounatsos

Related news

FDA approves much-debated Alzheimer’s drug panned by experts The Day
Hawaii , Japan , Switzerland , Cambridge
FDA conditionally approves controversial Alzheimer’s drug The Hindu
Phase 4 , Japan , Massachusetts , Cambridge
FDA approves Biogen’s controversial Alzheimer’s drug New York Post
Phoenix , Massachusetts , Cambridge
Panels find FDA, Biogen rushed Alzheimer’s drug nwaonline.com
Philadelphia , Cambridge
HFDA Approves Much-Debated Alzheimer’s Drug hamodia.com
Japan , Cambridge
Biogen dumps dubious Alzheimer’s drug after profit-killing FDA scandal Ars Technica
Phase 4 , Switzerland , Massachusetts , Cambridge
FDA approves Alzheimer’s drug that modestly slows disease pressherald.com
Massachusetts , Cambridge , Japan
First new Alzheimer’s drug in decades receives controversial FDA approval newatlas.com
Unmet , United States
The resurrection of a failed Alzheimer’s drug set to test FDA approval newatlas.com
San Diego
Alzheimer’s drug gets boost from FDA staff despite inconclusive note Seattle Times
Cambridge , United States
FDA approves debated Alzheimer’s drug panned by experts reviewjournal.com
Japan , Switzerland , Cambridge
Biogen Submits Promising Alzheimer’s Drug Aducanumab to FDA for Approval observer.com
FDA panel reviews 1st new Alzheimer’s drug in 2 decades staradvertiser.com
Mayo Clinic , United States , Japan , Cambridge
TFDA Approves Alzheimer’s Medication today.uconn.edu
Encarnación de Díaz
FDA Approved Alzheimer’s Drug Despite Some Staff Concerns wsj.com
Cambridge
MFDA chief tells reporters “transfer on” when pushing for approval of Biogen Alzheimer’s mvtelegraph.com
Wall Street , Massachusetts , Cambridge